Novelrad is a clinical-stage medical device company developing a proprietary transcatheter micro-suturing platform designed to bring surgical-quality suturing capabilities into minimally invasive cardiovascular interventions.

The company’s technology enables the deployment of precise multi-point sutures through a catheter-based approach, aiming to improve safety, reliability, and procedural efficiency in large-bore vascular and structural heart procedures. Novelrad’s platform is designed to mimic the surgical gold standard while simplifying complex catheterization workflows.

Novelrad has raised over $7M to date, including a €2.5M non-dilutive grant from the European Innovation Council, and is supported by an international network of clinical advisors, physicians, and strategic industry collaborators.